# C_2016221EN.01000501.xml

| 18.6.2016 | EN | Official Journal of the European Union | C 221/5 |
| --- | --- | --- | --- |

18.6.2016

EN

Official Journal of the European Union

C 221/5

---

Prior notification of a concentration

(Case M.7917 — Boehringer Ingelheim/Sanofi Animal Health Business)

(Text with EEA relevance)

(2016/C 221/05)

| 1. | On 8 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Boehringer Ingelheim group (BI, Germany), through its wholly owned subsidiary Boehringer Ingelheim International GmbH, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Sanofi’s animal health business (Merial, France), by way of purchase of shares and assets. |
| --- | --- |

1.

On 8 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Boehringer Ingelheim group (BI, Germany), through its wholly owned subsidiary Boehringer Ingelheim International GmbH, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Sanofi’s animal health business (Merial, France), by way of purchase of shares and assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   for BI: active worldwide in the development, production, distribution and marketing of pharmaceuticals, including prescription products, consumer healthcare products, biopharmaceuticals and animal health products,
  —   for Merial: producer of a wide range of animal pharmaceutical products and vaccines worldwide. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for BI: active worldwide in the development, production, distribution and marketing of pharmaceuticals, including prescription products, consumer healthcare products, biopharmaceuticals and animal health products,

for BI

—   for Merial: producer of a wide range of animal pharmaceutical products and vaccines worldwide.

for Merial

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7917 — Boehringer Ingelheim/Sanofi Animal Health Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7917 — Boehringer Ingelheim/Sanofi Animal Health Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---